

8 (amended). A bacteriophage as claimed in claim 1 which is a modified M13 bacteriophage wherein said first component of said recombinant protein is derived from the g3p protein.

10 (amended). A bacteriophage of claim 1 for use in the treatment or prophylaxis of *Helicobacter pylori* infection wherein the antibody variable region sequences of said recombinant polypeptide are variable region sequences of a monoclonal antibody selected from the monoclonal antibodies of hybridoma cell lines 5F8 (ECACC No.95121524), 2H6 (ECACC No. 95121526) and 5D8 (ECACC No.95121527).

12 (amended). A pharmaceutical composition comprising a bacteriophage as claimed in claim 1 in admixture with a pharmaceutically acceptable carrier or excipient.

13 (amended). A method for treatment of a bacterial infection in a mammal which comprises administering a bacteriophage of claim 1 to said mammal.

14 (amended). Use of a bacteriophage as claimed in claim 1 in the manufacture of a medicament for the treatment or prophylaxis of a mucosal bacterial infection.

REMARKS

Claims 1-16 are pending and under consideration. Claims 4-8, 10, and 12-14 have been amended to remove multiple dependencies. No issue of new matter is raised.

Please enter this amendment before calculation of filing fees.

Attached hereto is a page captioned "Version with markings to show changes made", which shows the amended claims with additions underlined and deletions bracketed.

No additional fee is believed to be necessitated by the foregoing amendments. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.